BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months
MLYS upcoming catalysts
Mineralys Therapeutics Inc.: 0 upcoming industry Phase 2/3 trial readout(s) in the next 90 days (0 Phase 3), 1 upcoming FDA decision event(s), and in the last 12 months 2 readout(s) and 1 FDA event(s). Subscribe to MLYS (.ics).
Drugs: lorundrostat
Upcoming FDA decision events
| Date | Event | Status | Company | Drug | Source |
|---|---|---|---|---|---|
| 2026-12-22 | PDUFA date (company-disclosed) | pending | Mineralys Therapeutics, Inc. MLYS | lorundrostat | PDUFA December 22, 2026 - Mineralys Therapeutics, Inc. (lorundrostat) |
Upcoming trial readouts
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| No trials in this window. | ||||||
FDA decision events, last 12 months
| Date | Event | Status | Company | Drug | Source |
|---|---|---|---|---|---|
| 2026-04-01 (quarter) | PDUFA date (company-disclosed) | date passed | Mineralys Therapeutics, Inc. MLYS | PDUFA second quarter of 2026 - Mineralys Therapeutics, Inc. |
Trial readouts, last 12 months
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2025-12-30 | P3 | Mineralys Therapeutics Inc. MLYS | NCT05968430 Open-Label Extension (OLE) Study to Assess Safety, Efficacy, and Tolerability of Lorundrostat in Subjects With Hypertension | Hypertension | active not recruiting | 1076 |
| 2025-12-17 | P2 | Mineralys Therapeutics Inc. MLYS | NCT06785454 A Study to Assess the Efficacy and Safety of Lorundrostat in Participants With Obstructive Sleep Apnea and Hypertension | Obstructive Sleep Apnea; Hypertension | completed | 48 |
Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line
results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are
company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA
(openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score.
Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP
readout_calendar / fda_decisions. Not investment advice.